000K  utf8
1100  2024$c2024-01-03
1500  eng
2050  urn:nbn:de:hbz:465-20250114-122734-4
2051  10.1186/s40658-023-00604-0
3000  Moraitis, Alexandros
3010  Bockisch, Andreas
3010  Fendler, Wolfgang Peter
3010  Fragoso Costa, Pedro
3010  Herrmann, Ken
3010  Jentzen, Walter
3010  Kersting, David
3010  Pöppel, Thorsten Dirk
3010  Reiter, Gloria
3010  Schmitz, Jochen
3010  Weber, Manuel
4000  Biodistribution and radiation dosimetry of ¹²⁴I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models  [Moraitis, Alexandros]
4209  Aim: Positron emission tomography (PET) using 124I-mIBG has been established for imaging and pretherapeutic dosimetry. Here, we report the first systematic analysis of the biodistribution and radiation dosimetry of 124I-mIBG in patients with neural crest tumours and project the results to paediatric patient models. Methods: Adult patients with neural crest tumours who underwent sequential 124I-mIBG PET were included in this retrospective single-center analysis. PET data were acquired 4, 24, 48, and/or 120 h after administration of a mean of 43 MBq 124I-mIBG. Whole-body counting and blood sampling were performed at 2, 4, 24, 48 and 120 h after administration. Absorbed organ dose and effective dose coefficients were estimated in OLINDA/EXM 2.2 according to the MIRD formalism. Extrapolation to paediatric models was performed based on mass-fraction scaling of the organ-specific residence times. Biodistribution data for adults were also projected to 123I-mIBG and 131I-mIBG. Results: Twenty-one patients (11 females, 10 males) were evaluated. For adults, the organs exposed to the highest dose per unit administered activity were urinary bladder (1.54 ± 0.40 mGy/MBq), salivary glands (0.77 ± 0.28 mGy/MBq) and liver (0.65 ± 0.22 mGy/MBq). Mean effective dose coefficient for adults was 0.25 ± 0.04 mSv/MBq (male: 0.24 ± 0.03 mSv/MBq, female: 0.26 ± 0.06 mSv/MBq), and increased gradually to 0.29, 0.44, 0.69, 1.21, and 2.94 mSv/MBq for the 15-, 10-, 5-, 1-years-old, and newborn paediatric reference patients. Projected mean effective dose coefficients for 123I-mIBG and 131I-mIBG for adults were 0.014 ± 0.002 mSv/MBq and 0.18 ± 0.04 mSv/MBq, respectively. Conclusion: PET-based derived radiation dosimetry data for 124I-mIBG from this study agreed well with historical projected data from ICRP 53. The effective dose coefficients presented here may aid in guidance for establishing weight-based activity administration protocols.
4950  https://doi.org/10.1186/s40658-023-00604-0$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:hbz:465-20250114-122734-4$xR$3Volltext$534
4961  https://duepublico2.uni-due.de/receive/duepublico_mods_00082282
5051  610
5550  124I-mIBG
5550  Dosimetry
5550  Effective dose
5550  Neural crest tumour
5550  PET